Search

everythinglearnresearchcommunity

for

Search:↓

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

The document is a detailed guide on skin conditions and treatments for dermatologists.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.

Hydroxychloroquine may help treat alopecia areata in children.

Advanced male pattern baldness affects the back of the scalp, reducing hair follicles.

The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.

The 2003 guidelines suggest that while some treatments can regrow hair in alopecia areata, none alter the disease's progression, and wigs may be the best option for extensive hair loss.

No cure exists for alopecia areata, and treatments are personalized.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.

Six genetic conditions are often linked to complete scalp hair loss in children.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.

HSP90 and lamin A/C are crucial for hair growth and could be targets for treating hair loss.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

The document concludes that alopecia has various forms, each with specific treatments, but no definitive cure for certain types like CCCA has been proven.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Low-Level Laser Therapy and other light treatments for hair growth lack strong evidence and need more research.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.